BIOMAT Database Logo BIOMAT Database Logo

Letter: Intravenous digoxin as a bioavailability standard. 1975

R G Stoll, and J G Wagner

UI MeSH Term Description Entries
D007275 Injections, Intravenous Injections made into a vein for therapeutic or experimental purposes. Intravenous Injections,Injection, Intravenous,Intravenous Injection
D004077 Digoxin A cardiotonic glycoside obtained mainly from Digitalis lanata; it consists of three sugars and the aglycone DIGOXIGENIN. Digoxin has positive inotropic and negative chronotropic activity. It is used to control ventricular rate in ATRIAL FIBRILLATION and in the management of congestive heart failure with atrial fibrillation. Its use in congestive heart failure and sinus rhythm is less certain. The margin between toxic and therapeutic doses is small. (From Martindale, The Extra Pharmacopoeia, 30th ed, p666) Digacin,Digitek,Digoregen,Digoxina Boehringer,Digoxine Nativelle,Dilanacin,Hemigoxine Nativelle,Lanacordin,Lanicor,Lanoxicaps,Lanoxin,Lanoxin-PG,Lenoxin,Mapluxin,Boehringer, Digoxina,Lanoxin PG,Nativelle, Digoxine,Nativelle, Hemigoxine
D006207 Half-Life The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity. Halflife,Half Life,Half-Lifes,Halflifes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D001682 Biological Availability The extent to which the active ingredient of a drug dosage form becomes available at the site of drug action or in a biological medium believed to reflect accessibility to a site of action. Availability Equivalency,Bioavailability,Physiologic Availability,Availability, Biologic,Availability, Biological,Availability, Physiologic,Biologic Availability,Availabilities, Biologic,Availabilities, Biological,Availabilities, Physiologic,Availability Equivalencies,Bioavailabilities,Biologic Availabilities,Biological Availabilities,Equivalencies, Availability,Equivalency, Availability,Physiologic Availabilities

Related Publications

R G Stoll, and J G Wagner
Intravenous digoxin as a bioavailability standard: slow infusion and rapid injection.
May 1974, Clinical pharmacology and therapeutics,
R G Stoll, and J G Wagner
Letter: Digoxin bioavailability.
November 1973, Journal of the American Pharmaceutical Association,
R G Stoll, and J G Wagner
Letter: Improving the bioavailability of digoxin.
June 1975, Lancet (London, England),
R G Stoll, and J G Wagner
Letter: Digoxin and the APhA bioavailability project.
November 1973, Journal of the American Pharmaceutical Association,
R G Stoll, and J G Wagner
Letter: Bioavailability of digoxin in presence of antacids.
October 1974, Journal of pharmaceutical sciences,
R G Stoll, and J G Wagner
Letter: Discrepancy between solution and bioavailability of digoxin tablets.
March 1975, Lancet (London, England),
R G Stoll, and J G Wagner
Letter: Discrepancy between solution and bioavailability of digoxin tablets.
March 1975, Lancet (London, England),
R G Stoll, and J G Wagner
Letter: Discrepancy between solution and bioavailability of digoxin tablets.
February 1975, Lancet (London, England),
R G Stoll, and J G Wagner
Letter: Digoxin bioavailability: paradoxical increased toxicity on dosage reduction.
August 1975, British medical journal,
R G Stoll, and J G Wagner
Digoxin bioavailability.
November 1978, Lancet (London, England),
Copied contents to your clipboard!